- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Anti thymocyte globulin.
Displaying page 1 of 2.
EudraCT Number: 2020-000419-56 | Sponsor Protocol Number: TCD601B101 | Start Date*: 2021-03-23 | |||||||||||
Sponsor Name:ITB-MED AB | |||||||||||||
Full Title: A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (si... | |||||||||||||
Medical condition: renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001269-40 | Sponsor Protocol Number: CT-1306 | Start Date*: 2008-10-29 |
Sponsor Name:Charité University Medicine | ||
Full Title: Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Th... | ||
Medical condition: Patients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids an... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002129-12 | Sponsor Protocol Number: P150955 | Start Date*: 2016-10-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: A randomized phase IIb study of cyclophosphamide (Cy) versus anti-thymocyte globulin (ATG) for the prophylaxis of graft-versus-host disease (GVHD) after reduced-intensity conditioning allogeneic pe... | |||||||||||||
Medical condition: Women and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicated | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002548-12 | Sponsor Protocol Number: TJB0702 | Start Date*: 2007-12-17 | |||||||||||
Sponsor Name:CHU-ULG | |||||||||||||
Full Title: Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings | |||||||||||||
Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005563-10 | Sponsor Protocol Number: TLI-001-2007 | Start Date*: 2007-11-30 | |||||||||||
Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS | |||||||||||||
Full Title: Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies | |||||||||||||
Medical condition: Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000902-55 | Sponsor Protocol Number: RATGAA07 | Start Date*: 2007-09-19 | |||||||||||
Sponsor Name:EBMT (European group for Blood and Marrow Transplantation) | |||||||||||||
Full Title: Prospective Phase II study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patie... | |||||||||||||
Medical condition: Acquired severe aplastic anaemia and transfusion dependent non-severe aplastic anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006495-16 | Sponsor Protocol Number: PrEPSo | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders | |||||||||||||
Medical condition: Covid 19 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002532-28 | Sponsor Protocol Number: ThymoHEMO1206 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase II Study of Efficacy of Rabbit Antithymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome | |||||||||||||
Medical condition: Low And Intermediate-1 Risk Myelodysplastic Syndrome in adult patients 70 years or younger | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) FR (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004364-35 | Sponsor Protocol Number: CETB115AUS01T | Start Date*: 2018-07-25 |
Sponsor Name:National Heart, Lung, and Blood | ||
Full Title: Eltrombopag added to standard immunosuppression in treatment-naïve severe aplastic anemia. | ||
Medical condition: Severe aplastic anemia (SAA) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2012-005538-12 | Sponsor Protocol Number: RG_12-264(HM2052) | Start Date*: 2013-08-21 | ||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||
Full Title: A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation | ||||||||||||||||||
Medical condition: Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003265-17 | Sponsor Protocol Number: S63466 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven) | |||||||||||||
Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D) | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005719-83 | Sponsor Protocol Number: ATGfamilystudy | Start Date*: 2007-01-30 | |||||||||||
Sponsor Name:University Hospital Hamburg-Eppendorf | |||||||||||||
Full Title: Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings... | |||||||||||||
Medical condition: acute lymphoblastic and myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006262-28 | Sponsor Protocol Number: IEO S438/508 | Start Date*: 2009-06-03 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory Triple Negative... | |||||||||||||
Medical condition: Patients with Refractory Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003078-33 | Sponsor Protocol Number: QRK306 | Start Date*: 2016-04-13 | |||||||||||
Sponsor Name:Quark Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death ... | |||||||||||||
Medical condition: QPI-1002 is being developed for the prevention of Delayed Graft Function in patients receiving renal transplants. The patient population of the current study will include patients undergoing deceas... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005862-30 | Sponsor Protocol Number: MHH-Pre-GvHD-001 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. | |||||||||||||
Medical condition: Pre-emptive therapy of acute graft versus host disease with prednisolone according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003282-36 | Sponsor Protocol Number: 123123 | Start Date*: Information not available in EudraCT |
Sponsor Name:Västra Götalands Regionen | ||
Full Title: A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation. | ||
Medical condition: Acute myeloid leukemia (AML) in children | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004598-83 | Sponsor Protocol Number: 54371254 | Start Date*: 2008-10-22 | |||||||||||
Sponsor Name:EBMT (European group for Blood and Marrow Transplantation) | |||||||||||||
Full Title: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous S... | |||||||||||||
Medical condition: Severe systemic sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001534-42 | Sponsor Protocol Number: TrRaMM4Gy | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies | |||||||||||||
Medical condition: Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched fa... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004730-34 | Sponsor Protocol Number: 361.11 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA | |||||||||||||
Full Title: A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transpla... | |||||||||||||
Medical condition: graft-versus-host disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001038-17 | Sponsor Protocol Number: MK-8228-040 | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in ... | |||||||||||||
Medical condition: Cytomegalovirus (CMV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
